Compare WTS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTS | CORT |
|---|---|---|
| Founded | 1874 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.6B |
| IPO Year | 1986 | N/A |
| Metric | WTS | CORT |
|---|---|---|
| Price | $278.75 | $88.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $271.40 | $139.00 |
| AVG Volume (30 Days) | 157.4K | ★ 663.7K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 16.19 | N/A |
| EPS | ★ 9.69 | 0.87 |
| Revenue | ★ $2,353,800,000.00 | $741,172,000.00 |
| Revenue This Year | $8.34 | $23.79 |
| Revenue Next Year | $6.11 | $40.97 |
| P/E Ratio | ★ $28.68 | $99.75 |
| Revenue Growth | 4.18 | ★ 17.92 |
| 52 Week Low | $177.59 | $49.00 |
| 52 Week High | $287.89 | $117.33 |
| Indicator | WTS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 68.54 |
| Support Level | $266.50 | $81.31 |
| Resistance Level | $281.60 | $87.19 |
| Average True Range (ATR) | 5.40 | 2.86 |
| MACD | 0.75 | 0.74 |
| Stochastic Oscillator | 84.20 | 93.81 |
Watts Water Technologies Inc is a U.S.-based company that provides safety, energy efficiency, and water conservation products. Its product portfolio includes residential and commercial flow control products, which are sold for plumbing and hot water applications; HVAC and gas products, including commercial boilers, water heaters, heating solutions, etc.; drainage and water reuse products, including drainage products and engineered rainwater-harvesting solutions; and water quality products, including point-of-use and point-of-entry water filtration, conditioning, and scale prevention systems. Its products are marketed through brands like Watts, Apex, Bradley, Nexa, and others. Geographically, the company derives its key revenue from the Americas, followed by Europe and the APMEA region.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.